Carlsmed (CARL) vs Avita Medical (RCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Avita Medical (RCEL) has outperformed Carlsmed (CARL) over the past year, gaining 312.1% versus a gain of 39.5%. Avita Medical is the larger company by market cap ($495.0 million vs $477.4 million), about 1.0 times the size, while Carlsmed is growing revenue faster (+85.9% vs +11.5%). Carlsmed converts more of its revenue into profit, with a net margin of -58.7% versus -67.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CARL | RCEL |
|---|---|---|
| Share price | $17.42 | $15.62 |
| Market cap | $477.38M | $494.96M |
| 1-day change | +1.16% | -2.31% |
| YTD return | +41.05% | +352.75% |
| 1-year return | +39.47% | +312.14% |
| 5-year return | — | +10.78% |
| EPS (TTM) | $-1.13 | $-1.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $50.51M | $71.61M |
| Revenue growth (YoY) | +85.94% | +11.45% |
| Net income (latest FY) | $-29.63M | $-48.59M |
| Gross margin | 75.31% | 82.13% |
| Operating margin | -60.53% | -59.40% |
| Net margin | -58.67% | -67.85% |
| 52-week high | $19.15 | $18.43 |
| 52-week low | $8.50 | $3.22 |
| Distance from 52-week high | -9.05% | -15.25% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +26.29% | +32.46% |
| Average volume | 112.80K | 417.02K |
| Shares outstanding | 27.40M | 31.69M |
| Employees | 127 | 226 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCEL has outperformed CARL by 272.7 percentage points over the past year.
- Carlsmed is more profitable, keeping -58.7 cents of every revenue dollar as net income versus -67.8 cents for Avita Medical.
- Carlsmed grew revenue faster in its latest fiscal year (+85.94% vs +11.45%).
About Carlsmed
CARL stock →Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures.
Health Care · Medical/Dental Instruments · 127 employees
About Avita Medical
RCEL stock →AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.
Health Care · Medical/Dental Instruments · 226 employees
CARL vs RCEL FAQ
Which is bigger, Carlsmed or Avita Medical?
Avita Medical (RCEL) is larger, with a market capitalization of $494.96M compared with $477.38M for Carlsmed (CARL).
Which stock has performed better over the past year, CARL or RCEL?
RCEL returned +312.14% over the past 12 months, compared with +39.47% for CARL (price return, excluding dividends). Past performance does not predict future results.
Are Carlsmed and Avita Medical in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.